New “One-Two Punch” to Fight Atherosclerosis

New “One-Two Punch” to Fight Atherosclerosis

HSP27 Vaccination Lowers Cholesterol AND Inflammation

Novel mechanism for upregulated LDL-R expression, lowering of PCSK9 and reduction in systemic, plaque and hepatic inflammatory biomarkers. 

Now in press at ATVB:

HSP27 combines with anti-HSP27 IgG antibodies to form immune complexes that dock at the hepatocyte cell membrane, engage the receptor TLR4, activate the NF-kB pathway and upregulate the expression of the LDL-R (independent of SREBP2). Plasma LDL cholesterol and PCSK9 levels fall because of the increased clearance by the more abundant LDL-Rs.

Inflammation biomarkers are markedly reduced in:
– blood (serum amyloid A levels drop >70%)
– liver (cytokines: IL-1beta, TNF-alpha)
– plaque (fewer macrophages & cholesterol crystals)

Net result: reduction in atherosclerosis